References of "Starkel, P."
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailInnovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC).
Dahlqvist, G.; Moreno, C.; Starkel, P. et al

in Acta Gastro-Enterologica Belgica (2021), 84(2), 347-359

Liver transplantation (LT) remains the only curative option for patients suffering from end-stage liver disease, acute liver failure and selected hepatocellular carcinomas and access to the LT-waiting ... [more ▼]

Liver transplantation (LT) remains the only curative option for patients suffering from end-stage liver disease, acute liver failure and selected hepatocellular carcinomas and access to the LT-waiting list is limited to certain strict indications. However, LT has shown survival advantages for patients in certain indications such as acute alcoholic hepatitis, hepatocellular carcinoma outside Milan criteria and colorectal cancer metastases. These newer indications increase the pressure in an already difficult context of organ shortage. Strategies to increase the transplantable organ pool are therefore needed. We will discuss here the use of HCV positive grafts as the use of normothermic isolated liver perfusion. Belgian Liver Intestine Advisory Committee (BeLIAC) from the Belgian Transplant Society (BTS) aims to guarantee the balance between the new indications and the available resources. [less ▲]

Detailed reference viewed: 65 (4 ULiège)
Full Text
Peer Reviewed
See detailHepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018
Peeters, M; De Somer, T; Klamer, S et al

in Journal of Hepatology (2020, August), 73

Detailed reference viewed: 44 (2 ULiège)
Full Text
Peer Reviewed
See detailHepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018
De Somer, T; Peeters, M; Klamer, S et al

in Acta Gastro-Enterologica Belgica (2020, March), 83(1), 12

Detailed reference viewed: 36 (0 ULiège)
Full Text
Peer Reviewed
See detailNew concepts in liver regeneration mechanisms in human severe alcoholic steatohepatitis.
Lejeune, A; Starkel, P; Louvet, A et al

in Acta Gastro-Enterologica Belgica (2019, March), 82(1), 12

Detailed reference viewed: 29 (2 ULiège)
Full Text
Peer Reviewed
See detailNew concepts in liver regeneration mechanisms in human severe alcoholic steatohepatitis.
Lejeune, A; Starkel, P; Louvet, A et al

in Hepatology (2018, October 18), 68(S1), 1378

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailStopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg serovconversion is associated with high relapse rates and fatal outcomes
Van Hees, S; Bourgeois, S; Van Vlierberghe, H et al

in Alimentary Pharmacology and Therapeutics (2018), 47(8), 1170-1180

Detailed reference viewed: 36 (6 ULiège)
Full Text
Peer Reviewed
See detailCessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
Van Hees, S; Bourgeois, S; Van Vlierberghe, H et al

in Hepatology (2017, October), 66(S1), 934

Detailed reference viewed: 24 (1 ULiège)
Full Text
Peer Reviewed
See detailSofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
Degré, D; Sersté, T; Lasser, L et al

in PLoS ONE (2017), 12(1), 0170933

Detailed reference viewed: 48 (2 ULiège)
Full Text
Peer Reviewed
See detailIntensive enteral nutrition is ineffective for individuals with severe alcoholic hepatitis treated with corticosteroids.
Moreno, C; Deltenre, P; Senterre, C et al

in Gastroenterology (2016), 150

BACKGROUND & AIMS: Severe alcoholic hepatitis (AH) is a lifethreatening disease for which adequate oral nutritional support is recommended. We performed a randomized controlled trial to determine whether ... [more ▼]

BACKGROUND & AIMS: Severe alcoholic hepatitis (AH) is a lifethreatening disease for which adequate oral nutritional support is recommended. We performed a randomized controlled trial to determine whether the combination of corticosteroid and intensive enteral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH. METHODS: We enrolled 136 heavy consumers of alcohol (age, 18–75 y) with recent onset of jaundice and biopsy-proven severe AH in our study, performed at 18 hospitals in Belgium and 2 in France, from February 2010 through February 2013. Subjects were assigned randomly (1:1) to groups that received either intensive enteral nutrition plus methylprednisolone or conventional nutrition plus methylprednisolone (controls). In the intensive enteral nutrition group, enteral nutrition was given via feeding tube for 14 days. The primary end point was patient survival for 6 months. RESULTS: In an intention-to-treat analysis, we found no significant difference between groups in 6-month cumulative mortality: 44.4% of patients died in the intensive enteral nutrition group (95% confidence interval [CI], 32.2%–55.9%) and 52.1% of controls died (95% CI, 39.4%– 63.4%) (P ¼ .406). The enteral feeding tube was withdrawn prematurely from 48.5% of patients, and serious adverse events considered to be related to enteral nutrition occurred in 5 patients. Regardless of group, a greater proportion of patients with a daily calorie intake less than 21.5 kcal/kg/day died (65.8%; 95% CI, 48.8–78.4) than patients with a higher intake of calories (33.1%; 95% CI, 23.1%–43.4%) (P < .001). CONCLUSIONS: In a randomized trial of patients with severe AH treated with corticosteroids, we found that intensive enteral nutrition was difficult to implement and did not increase survival. However, low daily energy intake was associated with greater mortality, so adequate nutritional intake should be a main goal for treatment. [less ▲]

Detailed reference viewed: 305 (10 ULiège)
Full Text
Peer Reviewed
See detailMulticenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.
Degré, D; Laleman, W; Verhelst, X et al

in Acta Gastro-Enterologica Belgica (2016, March), 79(1), 15

Detailed reference viewed: 30 (7 ULiège)
Full Text
Peer Reviewed
See detailSofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium
Moreno, C; Lasser, L; DELWAIDE, Jean ULiege et al

in Acta Gastro-Enterologica Belgica (2016, March), 79(1), 08

Detailed reference viewed: 32 (3 ULiège)
Full Text
Peer Reviewed
See detailSofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium
Moreno, C; Lasser, L; DELWAIDE, Jean ULiege et al

in Hepatology (2015, October), 62(1), 746

Background: All-oral, interferon-free regimens that combine direct-acting antiviral drugs have significantly advanced the treatment of hepatitis C (HCV), especially for genotype 1(G1) patients. However ... [more ▼]

Background: All-oral, interferon-free regimens that combine direct-acting antiviral drugs have significantly advanced the treatment of hepatitis C (HCV), especially for genotype 1(G1) patients. However, efficacy and safety data of interferon-free regimens in HCV genotype 4 (G4) patients are scarce. In Belgium, Sofosbuvir (SOF) and Simeprevir (SMV) treatment is available since January 2015 for G4 patients with advanced fibrosis (F3-F4 METAVIR) for 12 weeks. Methods: analysis of HCV G4 patients receiving SOF and SMV treatment in Belgium. The aim of the study was to evaluate the safety and efficacy of the treatment. Results: 73 G4 patients were enrolled in this data collection including 32 (43.8%) patients with severe fibrosis F3 and 41(56.2%) cirrhotic patients. The study population comprised 58.9% male, 77.8% treatment experienced patients. Median age was 59 [51-66] years and 5 patients were HCV/HIV co-infected. 24 patients received the treatment associated with ribavirin, 11/32 (34.37%) of patients with advanced fibrosis and 13/41 (31.71%) of cirrhotic patients. In cirrhotic patients, median MELD and Child-Pugh score were 9 [7-12.5] and 5 [5-6], 46.2% had platelet below 100.000/mm and 28.6% had albumin below 35 g/L. W4 HCV RNA was undetectable in 31.25% (15/48). 9 of the 15 patients with undetectable W4 HCV RNA received RBV. At W12, 100% (23/23) had HCV RNA below the limit of quantification, with 6/23 still detectable. All SVR12 data will be available at the time of presentation. No patient experienced serious adverse event. Conclusions: these preliminary results in difficult-to-treat G4 HCV patients show that SOF/SIM +/- RBV treatment is safe and seems promising, in line with that was observed in G1 HCV patients. [less ▲]

Detailed reference viewed: 101 (11 ULiège)
Full Text
Peer Reviewed
See detailMulticenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.
Degre, D; Laleman, W; Verhelst, X et al

in Acta Gastro-Enterologica Belgica (2015, March), 78(1), 03

Detailed reference viewed: 31 (4 ULiège)
Full Text
Peer Reviewed
See detailImpact of intensive enteral nutrition in association with corticosteroïds in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial
Moreno, C; Trepo, E; Louvet, A et al

in Acta Gastro-Enterologica Belgica (2015, March), 78(1), 01

Detailed reference viewed: 47 (2 ULiège)
Full Text
Peer Reviewed
See detailImpact of intensive enteral nutrition in association with corticosteroïds in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial
Moreno, C; Trepo, E; Louvet, A et al

in Hepatology (2014, October), 60(S1),

Intensive enteral nutrition by feeding tube does not improve 6-month survival in patients with severe alcoholic hepatitis. However, adequate nutritional support is associated with a better short-term ... [more ▼]

Intensive enteral nutrition by feeding tube does not improve 6-month survival in patients with severe alcoholic hepatitis. However, adequate nutritional support is associated with a better short-term prognosis. Adequate nutritional intake should be targeted in alcoholic hepatitis patients treated with corticosteroids. [less ▲]

Detailed reference viewed: 101 (3 ULiège)
Full Text
Peer Reviewed
See detailUpdate of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
Orlent, H; Deltenre, P; Francque, S et al

in Acta Gastro-Enterologica Belgica (2012), 75(2), 245-259

Detailed reference viewed: 80 (1 ULiège)
Full Text
Peer Reviewed
See detailThe influence of laboratory-induced Meld score differences on liver allocation: more reality than myth.
Schouten, J. N.; Francque, S.; Van Vlierberghe, H. et al

in Clinical Transplantation (2012), 26(1), 62-70

Background: Liver allocation in Eurotransplant (ET) is based on the MELD score. Interlaboratory MELD score differences in INR and creatinine determination have been reported. The clinical implication of ... [more ▼]

Background: Liver allocation in Eurotransplant (ET) is based on the MELD score. Interlaboratory MELD score differences in INR and creatinine determination have been reported. The clinical implication of this observation has not been demonstrated. Methods: MELD scores were calculated in 66 patients with liver cirrhosis using bilirubin, creatinine, and INR analyzed in six liver transplant centers. Based on allocation results of ET, patients transplanted from December 2006 to June 2007 were divided according to MELD score in four groups. For each group, the influence of the match MELD on the probability of receiving a transplant was studied (Cox proportional hazards model). Results: Laboratory-dependent significant differences in MELD score were demonstrated. Cox proportional hazards model showed a significant association between MELD score and the probability of organ allocation. The unadjusted hazard ratio for receiving a liver transplant was significantly different between group 2 and group 4 (group 2: MELD 19–24; group 4: MELD > 30). Conclusion: Laboratory-dependent significant differences in MELD score were observed between the six transplant centers. We demonstrated a significant association between the MELD score and the probability of organ allocation. The observed interlaboratory variation might yield a significant difference in organ allocation in patients with high MELD scores. [less ▲]

Detailed reference viewed: 41 (3 ULiège)
Full Text
Peer Reviewed
See detailManagement and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines
Colle, I.; Adler, M.; Brenard, R. et al

in Acta Gastro-Enterologica Belgica (2007), 70(4), 389-420

1. Introduction Chronic hepatitis B virus (HBV) infection currently affects about 400 million people and is responsible for 500,000 to 1,000,000 deaths annually worldwide from cirrhosis and hepatocellular ... [more ▼]

1. Introduction Chronic hepatitis B virus (HBV) infection currently affects about 400 million people and is responsible for 500,000 to 1,000,000 deaths annually worldwide from cirrhosis and hepatocellular carcinoma (HCC) (1). For this reason, screening high risk populations to identify HBV infected persons is important so that guidelines for treatment and prevention of transmission can be given in this specific group. Recently, new drugs became available for HBV and new insights in resistance and definitions came up. So, the purpose of this paper is providing an update of the recent literature and guidelines concerning 1. screening for chronic hepatitis B (CHB) 2. management of patients with CHB 3. treatment of CHB in mono-infected patients and in special patient populations (co-infected, transplanted and immunosuppressed patients). The recommendations are based onpublished information and the level of evidence is reported with each recommendation. The level of evidence is graded as :grade 1 : randomized controlled trials ; grade II-1 : controlled trials without randomization ; grade 11-2 : cohort or case-control analytic study ; grade 11-3 : multiple time series, dramatic uncontrolled experiments ; grade III : descriptive epidemiology, expert opinions. [less ▲]

Detailed reference viewed: 68 (0 ULiège)
Full Text
Peer Reviewed
See detailOutcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system
Adler, M; Lerut, J; Starkel, P et al

in Acta Gastro-Enterologica Belgica (2006, January), 69

Detailed reference viewed: 24 (1 ULiège)
Full Text
Peer Reviewed
See detailOutcome of patients with hepatocellular carcinoma listed for liver transplantation within the eurotransplant allocation system
Adler, M.; Lerut, J.; Starkel, P. et al

in Journal of Hepatology (2006), 44(Suppl. 2), 14

Detailed reference viewed: 21 (7 ULiège)